San Francisco, 29 January 2030: The Report Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), By Region (North America, Europe, APAC, ROW), And Segment Forecasts, 2023 - 2030

The global advanced therapy medicinal products market size is expected to reach USD 90.98 billion by 2030, registering a CAGR of 16.8% during the forecast period, according to a new report by Grand View Research, Inc. The ATMPs (Advanced Therapy Medicinal Products) exhibit the potential to cure diseases by addressing their root cause rather than symptomatic treatment. Thus, ATMPs help deliver transformative advantages which are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

The breakthrough approvals of Tecartus and Abecma post-approval of Zolgensma, Kymriah, and Yescarta have bolstered the exceptional advancements in this space. These approvals have spurred the investment flow in this arena thereby driving revenue growth. Key companies are adopting various operation models to accelerate the product manufacturing process.

Furthermore, the market witnessed several acquisitions by players that intended to enter or expand their existing business in this field. Acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene are some major & recent examples. These acquisitions depict the increasing interest of well-established pharma companies in this market. Increasing competition for gene therapy buyouts can lead to hefty premiums.

On the other hand, with the growing consumer demands, the ATMP manufacturers are outsourcing their product manufacturing thereby creating lucrative opportunities for the contract manufacturing organizations. Thus, several CDMOs have expanded their facilities. For instance, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million for the establishment of a new process development and manufacturing facility for advanced therapies and viral vectors.

The emergence of Advanced Therapy Medicinal Products (ATMPs) has transformed the pharmaceutical industry and disease treatment landscape. It has opened new routes for the treatment of incurable diseases and several cancer types. The success of products such as Kymriah, Zolgensma, and others is the key factor driving the market. The COVID-19 pandemic has triggered the application of advanced therapies in virology research to a major extent. A study was issued in December 2020 which stated the potential of T-cell therapy for the treatment of high-risk COVID-19 infected individuals. Prior to this, in September 2020, the U.S. FDA approved the ALVR109 (an allogeneic T-cell therapy IND application) designed for the treatment of COVID-19 patients.

Request sample report of Advanced Therapy Medicinal Products Market@ https://www.grandviewresearch.com/industry-analysis/advanced-therapy-medicinal-products-market/request/rs1

This is anticipated to drive investment in R&D of advanced therapy for SARS-CoV2 infections. Furthermore, a growing number of Mesenchymal Stromal/Stem Cells (MSCs) based clinical trials have been registered recently as a new treatment paradigm for SARS-CoV-2 infection. These therapies have shown promising results as the treatment modality in research programs, further supplementing the marketspace's organic revenue generation.

Advanced Therapy Medicinal Products Market Report Highlights

• The geographical expansion of Yescarta and Kymriah in Japan and Europe has encouraged the investors to support the development in this space
• Recent approvals of gene therapies have significantly accelerated the clinical trials in this segment
• COVID-19 pandemic has opened new areas for key players to invest in T-cell research for viral infections
• The research community is actively evaluating the potential of advanced therapies in COVID-19 patients, thereby aiding in market growth
• North America accounted for the largest revenue share in 2022 owing to the exponential rise in clinical trials pertaining to advanced therapies
• Strong pipeline of ATMPs in the U.S. accelerated revenue generation in the region
• Also, the shifting focus of U.S.-based companies from conventional drug development to ATMPS is driving regional growth
• In Asia Pacific, the market is expected to witness the fastest CAGR owing to expanding ATMP landscape in emerging markets such as China at the forefront
• Expanding business of China-based CDMOs has driven regional market growth
• Key companies are undertaking various strategic initiatives to maintain their market position. Collaboration between ViGeneron GmbH and Biogen Inc. in January 2021 is one of the notable examples of collaboration in this space
• The companies collaborated on the development of an AAV-based gene therapy product for the treatment of inherited eye diseases.

Although the market for advanced therapy medicinal products is currently in its nascent stage, it is continuously growing. Conventional drug manufacturers striving to gain a competitive edge are considering ATMPs as a lucrative source of revenue in future healthcare systems. Currently, this arena is very active, and companies are investing significantly in clinical trials of ATMPs post-success of approved products.

Advanced Therapy Medicinal Products Market Report Scope

Over the past years, several proteins and small molecule-based developing companies have begun focusing on the development of adoptive cell T therapies. For instance, in February 2022, Recipharm, a contract development and manufacturing organization (CDMO), expanded its advanced therapy medicinal products (ATMP’s) offering into virotherapy with the acquisition of Vibalogics.

The market for advanced therapy medicinal products has witnessed tremendous growth in the past few years. The increasing number of companies emerging in this arena is anticipated to intensify the competition in the market. Besides, recent approvals of ATMPs have accelerated the expansion in this area. The market players are undertaking various strategies to sustain their market position. Collaborations with contract manufacturing organizations are the current trend observed in this space. The CDMO/CMOs are witnessing high demand for their services owing to increasing R&D activity in this market.